ArticleBone marrow transplantation2026
Sequential quantification of T-cell receptor excision circles (TRECs) and K-deleting recombination excision circles (KRECs) and overall survival after allogeneic HSCT.
Article in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- T-cell receptor repertoires against HLA class I-restricted minor histocompatibility antigens are highly diverse with a small subset of public clonotypes.Journal for immunotherapy of cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of TRECs/KRECs in allogeneic HSCT (alloHSCT) has been limited by a lack of standard technical platforms to allow comparison and validation of results between centers. We quantified absolute TRECs/KRECs on sequential samples collected prospectively (pre-transplant, 1, 3, 6 and 12 months post-transplant) in 374 alloHSCT for hematological malignancies using LightCycler 480/TREC-KREC- ACTB (Roche Diagnostics). Following prompt decrease after transplant, KRECs recover as soon as 3 months posttransplant, while TRECs recovery takes up to 1 year (p < 0.001). KRECs do not associate with outcomes. However, higher pre-transplant TRECs strongly associate with reduced non-relapse mortality (NRM) and increased overall survival (OS), and remain independent in multivariate analysis (HR 0.37, p = 0.001, and HR 0.51, p < 0.001, respectively). In addition, faster TRECs recovery measured sequentially at 1, 3, 6 and 12 months after alloHSCT associates with better OS. Furthermore, landmark analyses showed that early survivors with higher TRECs levels at 6 and 12 months after alloHSCT had significantly better subsequent long-term survival, independent from graft-versus-host disease (GVHD) and other clinical factors in multivariate analysis (HR 0.33, p = 0.016 and HR 0.13, p < 0.001, respectively). TRECs levels pre-transplant and at 6 and 12 months post-transplant provide novel biomarker measurable data that associate with alloHSCT long-term outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.